|Dr. William K. McVicar||Pres, CEO & Director||751.11k||N/A||1958|
|Dr. Roderick MacKinnon||Co-Founder & Co-Chair of Scientific Advisory Board||42.13k||N/A||1956|
|Mr. John McCabe||CFO, Treasurer & Sec.||478.12k||N/A||1970|
|Dr. Thomas C. Wessel||Outside Advisor||481.16k||N/A||1956|
|Dr. Bruce Bean||Co-Founder, Co-Chair of Scientific Advisory Board & Board Observer||N/A||N/A||N/A|
Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Flex Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.